Nitrosative stress linked to sporadic Parkinson's disease: S

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Communicated by Stephen F. Heinemann, The Salk Institute for Biological Studies, La Jolla, CA, June 11, 2004 (received for review April 12, 2004)

This article has a Accurateion. Please see:

Accurateion for Yao et al., Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity, PNAS 2004 101:10810-10814 - September 03, 2004 Article Figures & SI Info & Metrics PDF

Abstract

Many hereditary and sporadic neurodegenerative disorders are characterized by the accumulation of aberrant proteins. In sporadic Parkinson's disease, representing the most prevalent movement disorder, oxidative and nitrosative stress are believed to contribute to disease pathogenesis, but the exact molecular basis for protein aggregation remains unclear. In the case of autosomal recessive-juvenile Parkinsonism, mutation in the E3 ubiquitin ligase protein parkin is linked to death of Executepaminergic neurons. Here we Display both in vitro and in vivo that nitrosative stress leads to S-nitrosylation of wild-type parkin and, initially, to a dramatic increase followed by a decrease in the E3 ligase-ubiquitin-proteasome degradative pathway. The initial increase in parkin's E3 ubiquitin ligase activity leads to autoubiquitination of parkin and subsequent inhibition of its activity, which would impair ubiquitination and clearance of parkin substrates. These findings may thus provide a molecular link between free radical toxicity and protein accumulation in sporadic Parkinson's disease.

Accumulation of misfAgeded proteins is thought to be a preExecuteminant factor in many neurodegenerative disorders (1–3). Rare hereditary mutations can simulate the commonSpace sporadic forms of the disease, resulting in fibrillization or frank aggregation of aberrant proteins in disorders as diverse as Parkinson's disease (PD), Alzheimer's disease, amyotrophic lateral sclerosis, polyglutamine triple repeat disorders, and tauopathies such as frontotemporal dementia (4, 5). In the case of PD, mutations in genes including parkin or α-synuclein can simulate the sporadic phenotype, which is believed to be induced by insults to mitochondrial complex I resulting in oxidative/nitrosative stress to the enExecuteplasmic reticulum and ubiquitin–proteasome systems (UPS), and consequent aberrant protein accumulation; Executepaminergic neurons appear to be particularly vulnerable to such insults, possibly Elaborateing the selective cell destruction in the substantia nigra that occurs in PD (6–9). Mutation in parkin, an E3 ubiquitin ligase that normally participates in ubiquitination and possibly chaperone activity, results in autosomal recessive-juvenile Parkinsonism (10). We noted that such E3 ligases contain cysteine residues in their RING Executemains, raising the possibility that cysteine thiol could react with nitric oxide (NO) species to form an S-nitrosylated derivative and thus influence biological activity (11–13). In this manner, S-nitrosylation of wild-type parkin would affect the ubiquitin–proteasome system degradative pathway and contribute to protein aggregation and thus the parkinsonian phenotype (2, 6, 8).

Materials and Methods

Fluorometric Detection of S-Nitrosothiols. The concentration of S-nitrosothiol formation was detected by conversion of the fluorescent compound 2,3-naphthyltriazole (NAT) from 2,3-diaminonaphthalene (DAN) at an emission wavelength of 360 nm and an excitation wavelength of 260 nm by using a Fluoro-Max-2 spectrofluorometer and datamax software (Instruments SA, Edison, NJ). Conversion to S-nitrosothiol is liArrive over the range 0.05–50 μM, as Characterized (14). NAT was prepared by dissolving 500 mg of DAN in 20 ml of glacial acetic acid, diluting the solution to 100 ml with distilled water on ice, then rapidly reacting it with 2.5 ml of 1.2 M NaNO2. The precipitated NAT was reWeepstallized three times from boiling water containing decolorizing carbon. The white needle-like Weepstal NAT had a melting point of 194°C. The fluorescence intensity curve of serial NAT dilutions was used to construct a standard curve.

Biotin-Switch Assay for Detection of S-Nitrosylated Proteins. Cell lysates and brain tissue extracts were prepared in HENC or HENT buffers (250 mM Hepes, pH 7.5/1 mM EDTA/0.1 mM neocuproine/0.4% 3-[(3-cholamiExecutepropyl)dimethylammonio]-1-propanesulfonate or 1% Triton X-100). Various amounts of protein were used for the assay, typically 500 μg for cell lysates and up to 7.5 mg for tissues. Blocking buffer [2.5% SDS/20 mM methyl methane thiosulfonate (MMTS) in HEN buffer] was mixed with the samples and incubated for 30 min at 50°C to block free thiol groups. After removing excess MMTS by acetone precipitation, nitrosothiols were then reduced to thiols with 1 mM ascorbate. The newly formed thiols were then linked with sulhydryl-specific biotinylating reagent N-[6-biotinamiExecute)-hexyl]-1′-(2′pyridyldithio) propionamide. We then pulled Executewn the biotinylated proteins with Streptavidin-agarose beads and performed Western blot analysis to detect the amount of parkin remaining in the samples (15).

Ubiquitination Assays. In vitro ubiquitination reactions were carried out by mixing immunoprecipitated parkin with 100 ng of E1 ubiquitin-activating enzyme (Calbiochem)/250 ng of E2 ubiquitin-conjugating enzyme (UbcH7, Boston Biochem, Cambridge, MA)/10 μg of ubiquitin (Sigma) in ubiquitination buffer (2 mM ATP/50 mM Tris/2.5 mM MgCl2 at pH 7.5) for 2 h at room temperature. Autoubiquitination of parkin was then detected by antiubiquitin antibody (Zymed). For the ex vivo ubiquitination assays, parkin-overexpressing SH-SY5Y neuroblastoma cells were transfected with the hemagglutinin (HA)-tagged ubiquitin and then exposed to S-nitrosocysteine (SNOC) or rotenone. The proteasome inhibitor MG132 (10 μM) was added to block the rapid degradation of polyubiquitinated proteins during the assay. Cell lysates were subjected to immunoprecipitation with anti-myc antibody, followed by Western blot analysis with anti-HA antibody. For assay of synphilin ubiquitination by parkin, we used HA-tagged synphilin-1 and myc-tagged ubiquitin.

Rotenone and 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration. All experiments were performed according to guidelines set by The Burnham Institute Animal Care Committee. Sprague–Dawley rats, weighing 200–250 g, were injected i.p. with freshly prepared rotenone (1 mg/kg per day in 50% DMSO and 50% polyethylene glycol) for 5 days. One group of animals received 3-bromo-7-nitroindazole (30 mg/kg per day) 30 min before rotenone injection. For the mouse experiments, neuronal NO synthase knockout and wild-type littermates, weighing 15–30 g, were injected with rotenone as above. Another group of C57BL/6 mice were injected with MPTP (30 mg/kg) i.p. for 4 days. Control animals were injected with vehicle only (5–10 animals per group).

Mass Spectrometry (MS). In-gel digestions were performed as Characterized (14). The peptides were extracted, dried under vacuum, and redissolved in 20 μl of 2% acetonitrile/0.1% formic acid in water. Nano-liquid chromatography (LC) MS analyses were carried out by using an LC Packings nano-LC system (Amsterdam) and a Micromass quadrupole time-of-flight (Q-TOF) API-US mass spectrometer (Manchester, U.K.). The analytical column was a PepMap C18 (LC Packings) with dimensions of 75 μm i.d. × 15 cm. Mobile phase A was 2% acetonitrile/0.1% formic acid, whereas mobile phase B was 80% acetonitrile/0.1% formic acid. The gradient was 2%∼ 40% mobile phase B in 75 min, followed by 100% mobile phase B for 5 min. The flow rate was ≈200 nl/min. The mass spectra of parkin and SNOC-exposed parkin were analyzed for cysteine alkylation, S-nitrosylation, and sulfination/sulfonation modifications, as well as for methionine oxidation by Mascot (Matrix Science, LonExecuten).

Molecular Modeling. We modeled the parkin RING I Executemain structure with the jackal molecular modeling package (16), using the related human c-Cbl Weepstal structure (PDB ID code 1FBV) as a template. The alignment of c-Cbl and parkin RING I protein sequences was generated by segment alignment algorithm (sea) software (17–19).

Results

S-Nitrosylation of Parkin in Vitro. Initially, we gathered three lines of chemical, biochemical, and immunochemical evidence to Display that parkin was S-nitrosylated by NO-related species in vitro. First, in a specific fluorescence assay for S-nitrosylated proteins, we demonstrated the reaction of recombinant parkin with the physiological NO Executenor, SNOC. This assay detects the formation of S-nitrosothiol by meaPositivement of the fluorescent compound NAT (14, 20). NAT is stoichiometrically converted from 2,3-diaminonaphthalene by NO released from S-nitrosylated proteins and thus provided a quantitative meaPositive of S-nitrosothiol formation on parkin. SNOC-treated recombinant GST-parkin resulted in significant S-nitrosothiol formation, whereas GST alone did not under these conditions (Fig. 1A ). To enPositive that the S-nitrosothiol generated under these conditions represented S-nitroso-parkin (SNO-PARK) rather than residual SNOC, the stability of S-nitrosothiols was examined at different incubation times. SNO-PARK was much more stable than SNOC alone; within 15 min of incubation, >95% of the SNOC had decayed, whereas SNO-PARK remained (14). This temporal separation allowed us to distinguish SNOC from SNO-PARK in the fluorescent S-nitrosothiol assay. Second, we Displayed that parkin was S-nitrosylated by SNOC by using the biotin-switch biochemical method (Fig. 1B ). In this assay, nitrosylated proteins are identified by Western blot after substituting SNO for a more stable biotin group via chemical reduction with ascorbate, an assay pioneered by Snyder and colleagues (15). Third, we obtained immunoblot evidence for SNO-PARK formation by colabeling of the same band with an antibody specific for parkin and an antibody specific for S-nitrosylated protein (Fig. 1C ) (21).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

S-nitrosylation of parkin in vitro. (A) Recombinant protein GST-parkin (0.2μM) was incubated with SNOC (200μM) for 30 min at room temperature (RT). The SNO-PARK thus generated was assessed by release of NO, causing the conversion of 2,3-diaminonaphthalene to the fluorescent compound NAT. GST protein alone was used as negative control. BSA (5 μM) was used as positive control (25). SNOC itself quickly decayed and thus resulted in insignificant S-nitrosothiol readings in this assay. (B)(Upper) Cell lysates from human neuroblastoma SH-SY5Y cells overexpressing myc-tagged parkin were incubated with 200 μM SNOC at RT. Control samples were subjected to decayed SNOC under the same conditions. Thirty minutes after SNOC expoPositive, SNO-PARK was detected by the biotin-switch assay (15). w/o Biotin-HPDP represents the control without biotin linker [N-[6-biotinamiExecute)hexyl]-1′-(2′pyridyldithio) propionamide] (Lower) Total parkin in cell lysates identified by immunoblot. (C) (Upper) Cell lysates were immunoprecipitated with anti-myc antibody. The immunoprecipitates were incubated with or without SNOC and subjected to SDS/PAGE Western analysis under nonreducing conditions. The membrane was blotted with anti-S-nitrosylated protein antibody to identify nitrosylated parkin and revealed an ≈2-fAged increase after SNOC expoPositive by densitometry. (Lower) Same blot reprobed with anti-parkin antibody to verify equal loading.

Regulation of Parkin E3 Ubiquitin Ligase Activity by S-Nitrosylation. To determine whether S-nitrosylation of parkin affected its E3 ligase activity, we performed an in vitro E3 ligase assay comparing activity of wild-type parkin and SNO-PARK. We found that expoPositive of parkin to SNOC resulted in a dramatic increase in its E3 ligase activity, monitored by the autoubiquitination of parkin (Fig. 2A ). To confirm that these in vitro findings were relevant to the cellular milieu, we incubated parkin-transfected, Executepaminergic SH-SY5Y cells with SNOC or with the mitochondrial complex I inhibitor rotenone, which is known to induce the parkinsonian phenotype (22). We then monitored SNO-PARK formation and parkin E3 ligase activity. We found that either SNOC or rotenone led to the generation of SNO-PARK by the biotin-switch assay (Fig. 2B ). In both cases, within a few hours of expoPositive to SNOC or rotenone, the resulting S-nitrosylation significantly increased the E3 ligase activity of parkin in SH-SY5Y cells lysates (Fig. 2C ). Fascinatingly, if assayed 12–24 h after expoPositive to the physiological NO Executenors SNOC or S-nitrosoglutathione, or to rotenone, parkin E3 ligase activity began to decrease (Fig. 2D ). Similarly, parkin E3 ligase activity increased 2 h after NO expoPositive but began to decrease by 24 h with synphilin-1 as the substrate (Fig. 2E ). This biphasic action would be expected if S-nitrosylation initially activated E3 ligase activity, and the resulting autoubiquitination of parkin subsequently led to its inactivation. Moreover, Impressed increases in ubiquitinated proteins can potentially overwhelm the proteasome and result in aberrant protein accumulation, as has been observed with parkin in Lewy bodies of PD patients (6, 7, 23). As controls, Hoechst staining revealed that the cells were still alive at the time of the parkin E3 ligase activity assay and that there was no Trace on the assay after incubation of purified parkin directly with rotenone (data not Displayn).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Regulation of parkin E3 ubiquitin ligase activity by S-nitrosylation. (A) In vitro S-nitrosylation of parkin up-regulates its E3 ligase activity. (Upper) Lysates from parkin-overexpressing SH-SY5Y cells were immunoprecipitated with anti-myc antibody. The immunoprecipitates were incubated with SNOC (200 μM) and then subjected to in vitro ubiquitination reaction. SNOC increased the autoubiquitination of parkin, detected by anti-ubiquitin antibody. (Lower) Parkin loading control. (B) S-nitrosylation of parkin after SNOC or rotenone expoPositive. (Upper) Cell lysates from SH-SY5Y cells that had been exposed to SNOC (SNOC Ex Vivo) or rotenone (1 μM for 6 h) were subjected to the biotin-switch assay to detect SNO-PARK. Also, cell lysates were exposed to SNOC directly (SNOC In Vitro). Rotenone expoPositive was supplemented with l-arginine (labeled l-Arg) as a NOS substrate. Both SNOC and rotenone increased SNO-PARK in these assays. Nω-nitro-l-arginine (NNA) was used as a NOS inhibitor and suppressed SNO-PARK formation. (Lower) Parkin loading control. (C) Ex vivo S-nitrosylation of parkin up-regulates its E3 ligase activity. SH-SY5Y cells were transfected with HA-tagged ubiquitin and exposed to SNOC or rotenone to nitrosylate parkin. Cell lysates were then subjected to immunoprecipitation with anti-myc followed by Western blot analysis with anti-HA to detect autoubiquitinated parkin. NNA prevented the rotenone-induced increase in E3 ligase activity. (D) Trace of NO Executenor SNOC and rotenone on parkin E3 activity at different times. SH-SY5Y cells were exposed to SNOC or rotenone. At early time points (2 h after SNOC or 6 h after rotenone), parkin autoubiquitination increased compared with control but decreased several hours later. (E) Trace of NO Executenor on ubiquitination of synphilin-1 (Syn-1) by parkin. SH-SY5Y cells were cotransfected with HA-synphilin-1 and myc-ubiquitin and exposed to SNOC. Synphilin-1 ubiquitination increased 2 h after SNOC expoPositive but decreased 24 h later. Aged SNOC, decayed SNOC.

S-Nitrosylation of Parkin in PD Animal Models and in Human PD Brain. We next Questioned whether the SNO-PARK that we encountered in vitro and in cell-based assays after S-nitrosylation was also present in vivo in rodent parkinsonian models induced by the mitochondrial complex I inhibitors rotenone or MPTP, as well as in human brains with sporadic PD. We first examined the substantia nigra and striatum of rats that had been injected with rotenone and found SNO-PARK formation by the biotin-switch assay compared to vehicle-injected control rats (Fig. 3A ). Additionally, SNO-PARK was observed in the brains of MPTP-injected mice (Fig. 3B ). Finally, we examined human brains with sporadic PD with diffuse Lewy bodies (versus autopsy brains from patients who died of other causes) and found evidence for SNO-PARK formation by the biotin-switch method (Fig. 3C and Fig. 6, which is published as supporting information on the PNAS web site).

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

S-nitrosylation of parkin in rodent models and human PD brain. (A) Vehicle (control), rotenone, or rotenone plus the relatively specific neuronal NO synthase inhibitor 3-bromo-7-nitroindazole (3br7NI) was i.p. injected into Sprague–Dawley rats (26). (Upper) Brain extracts from substantia nigra and striatum were subjected to the biotin-switch assay to detect SNO-PARK. Rotenone resulted in increased SNO-PARK that was partially abrogated by 3br7NI. (Lower) Parkin loading control. (B) SNO-PARK was detected in MPTP-, but not control-, injected mice. (C) SNO-PARK was detected in representative temporal cortex of human brain extracts from two sporadic PD patients with diffuse Lewy bodies but not from control brain by using the biotin-switch assay. In total, we tested four brain samples from PD, two normal controls with no CNS disease, two controls with Alzheimer's disease, and two controls with Huntington's disease (see Fig. 6). Each of the PD brain samples, but none of the control brains, manifests evidence for SNO-PARK formation (P < 0.01 by χ2 test).

If S-nitrosylation of parkin and consequent increase in E3 ligase activity occur because of reaction with NO in neurons, then inhibition of NO synthase (NOS) activity should abrogate the Trace. Therefore, we pretreated with a NOS inhibitor an aliquot of rotenone-exposed SH-SY5Y cells stably transfected with parkin to see whether we could block SNO-PARK formation and attenuate the increase in E3 ligase activity. Indeed, we found that NOS inhibition prevented these Traces (Fig. 2 B and C ). Additionally, pharmacological inhibition or genetic disruption of neuronal NO synthase prevented the formation of SNO-PARK observed in vivo in rotenone-exposed rodents (Fig. 3A and data not Displayn).

Peptide Mass Fingerprinting Analysis of Recombinant Human Parkin. It is most Necessary to link structure with function, that is, to identify the critical cysteine residue(s) in parkin whose S-nitrosylation regulates the E3 ligase activity. Therefore, as a first step to further identify the chemical nature of the NO-triggered-modification of the parkin E3 ligase responsible for activation and assess the possibility of additional oxidative products, we conducted peptide mass fingerprinting. Mass spectra were obtained after in-gel digestion by trypsin of human recombinant parkin using quadrupole time-of-flight (Q-TOF) MS with methods that we have Characterized (14). With MS, we found that five of seven cysteines in the RING I Executemain of parkin are candidates to be S-nitrosylated; however, it will be Necessary in the future to deliTrime which of these nitrosylated cysteines are responsible for the altered E3 ligase activity. Moreover, as we have Characterized for activation of matrix metalloproteinase enzymes (14), these cysteine residues can undergo further oxidation to sulfinic or sulfonic acid derivatives (Fig. 4 and Fig. 7, which is published as supporting information on the PNAS web site); whether these oxidized products are relevant to the functional activity of the enExecutegenous E3 ligase, however, remains unknown. Additionally, we observed that five other cysteines in the in-between-RING and RING II Executemains were potentially S-nitrosylated and/or sulfonated (Table 1, which is published as supporting information on the PNAS web site). Analysis of Weepstal structure models of the parkin RING I Executemain revealed that two of the cysteines lie within the consensus motif for S-nitrosylation that we had identified, making them likely candidates for physiological nitrosylation (Fig. 5) (13).

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Peptide mass fingerprinting analysis of the modified MS thiol group of cysteine residues within the highly conserved RING I Executemain of recombinant human parkin exposed to SNOC. (Upper) Quadrupole time-of-flight (Q-TOF) results for RING I Executemain of recombinant parkin exposed to SNOC. Sequences containing modified cysteines. CarbamiExecutemethyl (CAM) signifies modification by ioExecuteacetamide alkylation to protect free cysteines before trypsin digestion. Cys-SNO indicates S-nitrosothiol formation; Cys-SO2H or Cys-SO3H indicates sulfinic or sulfonic acid derivatization, respectively. Previously, we had Displayn that nitrosylation can pDepart further oxidation to these derivatives (14). Five of the seven cysteine residues in the RING I Executemain underwent modification. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. (Lower) Schematic representation of parkin and sample mass spectra of parkin modifications in RING I Executemain (bars indicate tryptic fragments containing modified cysteine residues). Ubl, ubiquitin-like Executemain; IBR, in-between RING Executemain. For additional mass spectra results on the RING II and IBR Executemains, see Fig. 7 and Table 1.

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Model of S-nitrosylation of parkin. Ribbon structure of a partial sequence of human parkin Displaying RING I Executemain (residues 237Thr to 291Ala). α-Helix Displayn in red, β-sheet in cyan, cysteine residues in green, histidine in yellow, aspartate in red, and arginine in blue. 241Cys and 260Cys match the nitrosylation consensus motif (13).

Discussion

In summary, we found that S-nitrosylation of parkin can stimulate its E3 ligase activity, resulting in an initial increase in enzyme activity, autoubiquitination, and thereafter subsequent decrease in activity. We speculate that the initial increase in parkin's ubiquitin E3 ligase activity and its autoubiquitination may result in proteasome dysfunction and protein accumulation. Moreover, the subsequent decrease in parkin's ubiquitin E3 ligase activity may impair ubiquitination of parkin substrates and hence the neuroprotective Trace that has been observed with parkin overexpression. This biphasic process may repeat itself throughout the course of the disease as additional molecules of parkin are nitrosylated and oxidized. We found evidence for SNO-PARK formation in both animal models of mitochondrial complex I deficiency and in human brains of patients with sporadic PD and diffuse Lewy body disease.

Executepaminergic neurons are particularly vulnerable to ubiquitin-proteasome system (UPS) dysfunction, and interference with this degradation system may lead to aberrant protein accumulation and cell death. Hence, nitrosative and oxidative stress resulting in parkin dysfunction may provide a mechanistic link between free radical production, UPS deficits, protein accumulation, and Executepaminergic neuronal demise in sporadic PD. The elucidation of an NO-mediated pathway to neuronal apoptosis involving parkin dysfunction may contribute to the development of new therapeutic Advancees for sporadic PD and other disorders associated with protein accumulation due to nitrosative and oxidative stress. Additionally, the activity of other RING-finger E3 ligases may also be affected by S-nitrosylation, providing a heuristic framework for the pathogenesis of other neurodegenerative and systemic disorders.

Note. After submission of this manuscript, another group reported that parkin was S-nitrosylated in sporadic PD (24). These authors also found that overexpression of parkin rescued neuronal cell lines subjected to proteasome inhibition and this protective Trace was prevented by S-nitrosylation of parkin, supporting the pathophysiological relevance of SNO-PARK formation. However, that work reported that parkin E3 ligase activity was decreased after S-nitrosylation. We feel that the discrepancy with our observation of an initial increase in parkin E3 ligase activity followed by a decrease can be Elaborateed by our Inspecting at earlier time points after S-nitrosylation and by other methoExecutelogical Inequitys in the E3 ligase assays, such as our inclusion of a proteasome inhibitor in the E3 ligase assays.

Acknowledgments

We thank Dr. Executenger Zhang (The Scripps Research Institute, La Jolla, CA) for the constructs of ubiquitin and Dr. Yuzhen Ye for modeling and illustration of the parkin Weepstal structure. This work was supported in part by National Institutes of Health Grants P01 HD29587, R01 EY09024, R01 EY05477, and R01 NS41207 and the American Parkinson's Disease Association, San Diego Chapter.

Footnotes

↵ ∥ To whom corRetortence should be addressed. E-mail: slipton{at}burnham.org.

↵ † D.Y., Z.G., T.N., and Z.-Q.S. contributed equally to this work.

Abbreviations: NAT, 2,3-naphthyltriazole; SNOC, S-nitrosocysteine; SNO-PARK, S-nitroso-parkin; HA, hemagglutinin; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson's disease; NOS, NO synthase.

Copyright © 2004, The National Academy of Sciences

References

↵ Mayer, R. J., Lowe, J., Lennox, G., Executeherty, F. & LanExecuten, M. (1989) Prog. Clin. Biol. Res. 317 , 809-818. pmid:2557642 LaunchUrlPubMed ↵ Bence, N. F., Sampat, R. M. & Kopito, R. R. (2001) Science 292 , 1552-1555. pmid:11375494 LaunchUrlAbstract/FREE Full Text ↵ GAgedberg, A. L. (2003) Nature 426 , 895-899. pmid:14685250 LaunchUrlCrossRefPubMed ↵ Perutz, M. F. & Windle, A. H. (2001) Nature 412 , 143-144. pmid:11449262 LaunchUrlCrossRefPubMed ↵ Yong, V. W., Power, C., Forsyth, P. & Edwards, D. R. (2001) Nat. Rev. Neurosci. 2 , 502-511. pmid:11433375 LaunchUrlCrossRefPubMed ↵ Dawson, T. M. & Dawson, V. L. (2003) Science 302 , 819-822. pmid:14593166 LaunchUrlAbstract/FREE Full Text ↵ Giasson, B. I. & Lee, V. M. (2003) Cell 114 , 1-8. pmid:12859888 LaunchUrlCrossRefPubMed ↵ Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. & Mucke, L. (2000) Science 287 , 1265-1269. pmid:10678833 LaunchUrlAbstract/FREE Full Text ↵ Zhang, Y., Dawson, V. L. & Dawson, T. M. (2000) Neurobiol. Dis. 7 , 240-250. pmid:10964596 LaunchUrlCrossRefPubMed ↵ Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. & Shimizu, N. (1998) Nature 392 , 605-608. pmid:9560156 LaunchUrlCrossRefPubMed ↵ Lipton, S. A., Choi, Y. B., Pan, Z. H., Lei, S. Z., Chen, H. S., Sucher, N. J., Loscalzo, J., Singel, D. J. & Stamler, J. S. (1993) Nature 364 , 626-632. pmid:8394509 LaunchUrlCrossRefPubMed Stamler, J. S. (1994) Cell 78 , 931-936. pmid:7923362 LaunchUrlCrossRefPubMed ↵ Stamler, J. S., Toone, E. J., Lipton, S. A. & Sucher, N. J. (1997) Neuron 18 , 691-696. pmid:9182795 LaunchUrlCrossRefPubMed ↵ Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C. & Lipton, S. A. (2002) Science 297 , 1186-1190. pmid:12183632 LaunchUrlAbstract/FREE Full Text ↵ Jaffrey, S. R., Erdjument-Bromage, H., Ferris, C. D., Tempst, P. & Snyder, S. H. (2001) Nat. Cell Biol. 3 , 193-197. pmid:11175752 LaunchUrlCrossRefPubMed ↵ Xiang, Z. & Honig, B. (2001) J. Mol. Biol. 311 , 421-430. pmid:11478870 LaunchUrlCrossRefPubMed ↵ Ye, Y., Jaroszewski, L., Li, W. & Godzik, A. (2003) Bioinformatics 19 , 742-749. pmid:12691986 LaunchUrlAbstract/FREE Full Text Zheng, N., Wang, P., Jeffrey, P. D. & Pavletich, N. P. (2000) Cell 102 , 533-539. pmid:10966114 LaunchUrlCrossRefPubMed ↵ Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) Nature 416 , 703-709. pmid:11961546 LaunchUrlCrossRefPubMed ↵ Wink, D. A., Kim, S., Coffin, D., Cook, J. C., VoExecutevotz, Y., ChistoExecuteulou, D., Jourd'heuil, D. & Grisham, M. B. (1999) Methods Enzymol. 301 , 201-211. pmid:9919568 LaunchUrlCrossRefPubMed ↵ Gow, A. J., Chen, Q., Hess, D. T., Day, B. J., Ischiropoulos, H. & Stamler, J. S. (2002) J. Biol. Chem. 277 , 9637-9640. pmid:11796706 LaunchUrlAbstract/FREE Full Text ↵ Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V. & Greenamyre, J. T. (2000) Nat. Neurosci. 3 , 1301-1306. pmid:11100151 LaunchUrlCrossRefPubMed ↵ Schlossmacher, M. G., Frosch, M. P., Gai, W. P., Medina, M., Sharma, N., Forno, L., Ochiishi, T., Shimura, H., Sharon, R., Hattori, N., et al. (2002) Am. J. Pathol. 160 , 1655-1667. pmid:12000718 LaunchUrlCrossRefPubMed ↵ Chung, K. K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, V. L. & Dawson, T. M. (2004) Science, 304 , 1328-1331. pmid:15105460 LaunchUrlAbstract/FREE Full Text ↵ Stamler, J. S., Simon, D. I., Osborne, J. A., Mullins, M. E., Jaraki, O., Michel, T., Singel, D. J. & Loscalzo, J. (1992) Proc. Natl. Acad. Sci. USA 89 , 444-448. pmid:1346070 LaunchUrlAbstract/FREE Full Text ↵ He, Y., Imam, S. Z., Executeng, Z., Jankovic, J., Ali, S. F., Appel, S. H. & Le, W. (2003) J. Neurochem. 86 , 1338-1345. pmid:12950443 LaunchUrlCrossRefPubMed
Like (0) or Share (0)